

- Routine Aboriginal schedules have been revised to simply include the 'Routine Aboriginal infant series' with associated footnote C which indicates that aboriginal children remain eligible for hepatitis A vaccine up to and including 18 years of age, using the age-appropriate dosing and schedule.
- HAVRIX® 1440 and HAVRIX® 720 JUNIOR: the age recommendations for these vaccines have been revised to:
 - HAVRIX® 720 JUNIOR: 6 months – 18 years of age (inclusive)
 - HAVRIX® 1440: 19 years of age and older

Content related to a 1.0 mL dose for individuals 16-18 years of age (inclusive) has been removed. HAVRIX® 1440 is now available in a vial format and therefore a 0.5 mL dose can be withdrawn from the adult formulation for those 16-18 years of age, if required. This is in accordance with the product monograph indication for a 720 ELU dosage for those up to 18 years of age (inclusive). As such, the following content has been added to SPECIAL CONSIDERATIONS: "In order to address the gaps in age approvals for hepatitis A vaccines in Canada, a 0.5 mL dose of HAVRIX® 1440 can be used for adolescents 16-18 years of age (inclusive), if required".

- SEROLOGICAL TESTING: Content has been added indicating that serological testing may be indicated prior to immunization for select special populations, see *Section III-Immunization of Special Populations*.
- PRODUCT COMPONENTS has been updated.
- SPECIAL CONSIDERATIONS: content related to the use of hepatitis A vaccine and/or Ig for travelers to hepatitis A endemic areas has been removed. The following content has been added: "For more information related to pre-exposure prophylaxis against hepatitis A related to travel, refer clients to their local travel clinic."
- ADVERSE EVENTS has been updated.

Please remove page numbers: 5-10 dated January 2012-June 2015
Please add new page numbers: 5-10a dated February 2017

Hepatitis A and B Vaccine Combined (TWINRIX® and TWINRIX® Junior)

- Pages have been reformatted.
- TWINRIX® and TWINRIX® Junior product pages have been consolidated into one product page.
- INDICATIONS: revised to indicate that these vaccines are not currently publicly funded.
- DOSES AND SCHEDULE: the rapid dosing schedule has been removed. Footnote B has been added, which indicates, "For information on a rapid dosing schedule for TWINRIX® and TWINRIX® Junior, refer to a travel clinic".

- Footnote B content related to TWINRIX® Junior age approvals has been updated to reference NACI's recommendation that hepatitis A vaccine may be provided beginning at 6 months of age, to infants who are at increased risk of infection or severe hepatitis A.
- PRODUCT COMPONENTS has been updated.

Please remove page numbers: 22 & 23 dated June 2015
Please add new page numbers: 22 & 23 dated February 2017

Please also remove the Table of Contents for Section VII-Biological Products dated January 2017 and replace with the enclosed updated Table of Contents dated February 2017.

If you have any questions or concerns, please contact Christine Halpert, Senior Practice Leader, BCCDC at telephone (604) 707-2555 or by email at christine.halpert@bccdc.ca or Stephanie Meier, Public Health Resource Nurse, BCCDC at telephone (604) 707-2577 or by email at stephanie.meier@bccdc.ca.

Sincerely,



Monika Naus MD MHSc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc: BC Ministry of Health:
Dr. Perry Kendall
Provincial Health Officer

Dr. Bonnie Henry
Deputy Provincial Health Officer

Craig Thompson
Director, Provincial Immunization Services

Warren O'Briain
Executive Director, Public Health Services & Office of Aboriginal Health

Page 3 of 3